Register to:

  • Save your health matches
  • Ask questions
  • Connect with others
  • Get the latest on clinical trials
Register Now

Already a member?
Sign In

Inspire others by sharing your story

Share Story

Share with others things you have tried, so they can learn from your experiences

Write Review

Clinical Trials

| All Clinical Trials | Go Back To Home Page

Study ID: NCT00708942

Title: A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-Grade Cervical Intraepithelial Neoplasia (CIN1)

Status:
Not Yet Recruiting
Phase:
2

Trial Contact Information

Principal Contact:
Mariann Jeremiassen, Cand.scient.
Principal Phone:
47-2206-2210
Principal Email:
mj@photocure.no

Sponsor(s): PhotoCure

Condition(s):
Cervical Cancer
Cervical Dysplasia
Cancer
Cervical Intraepithelial Neoplasia
Neoplasms

Purpose: The study will examine the effect of HAL vs placebo photodynamic therapy of low-grade cervical precancerous lesions (dysplasia) in women.

Eligibility:
Minimum Age:
18 Years
Accepts Healthy Volunteers:
No

Inclusion Criteria:

- Satisfactory colposcopy examination

- Negative endocervical canal by colposcopy

- Ectocervical CIN1 as verified by local pathologist (biopsy).

- Colposcopical visible lesion at visit 2, before photoactivation

- Written Informed Consent signed

- Age 18 or above

Exclusion Criteria:

- Previous treatment of CIN or invasive disease or suspicion of either micro-invasive
or invasive disease

- Malignant cells on cytology or histology

- Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology

- Suspicion of endocervical disease on colposcopy

- Current pelvic inflammatory disease, cervicitis, or other gynecological infection as
per colposcopy and clinical examination

- Known or suspected porphyria

- Patients who have received one or more shots of a prophylactic HPV vaccine
(e.g.Gardasil or Cervarix)

- Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate
or aminolevulinic acid)

- Pregnancy

- Nursing

- Childbirth or miscarriage within six weeks of enrolment - Known

- Participation in other "competitive" clinical studies either concurrently or within
the last 30 days

- Risk of poor protocol compliance

- Not willing to use adequate birth control from screening until last PDT

- Subject is the investigator or any sub-investigator, research assistant, pharmacist,
study coordinator, other staff or relative thereof directly involved in the conduct
of the protocol.

Other Location(s): Lille, France,Hannover, Germany,Oslo, Norway

Terms: This is an abstract courtesy of ClinicalTrials.gov, a service of the US National Institute of Health Developed by the National Library of Medicine. ClinicalTrials.gov provides regularly updates information about federally and privately supported clinical research in human volunteers.

arrow 26 People Experienced Clinical Trials

See All

Feedback